Sydney, Jan 21, 2026, 17:33 AEDT — Markets have closed for the day.
- Telix shares closed at A$10.61, slipping 7.7%
- Company signaled FY2025 revenue will meet guidance and highlighted initial traction with Gozellix
- China’s regulator has accepted the Illuccix filing, starting the formal review process
Telix Pharmaceuticals shares dropped 7.7% on Wednesday, settling at A$10.61. The decline came as investors digested a new quarterly update alongside a regulatory move in China related to its prostate cancer imaging business.
This move is significant as Telix’s valuation remains heavily dependent on growth in its commercial scans, even as the market watches closely for progress in its broader pipeline, which has faced regulatory hurdles in the United States.
Late Tuesday, Telix reported unaudited full-year group revenue of roughly US$804 million, matching its upgraded forecast. Fourth-quarter revenue stood near US$208 million. The U.S. launch of Gozellix, following reimbursement approval, boosted its precision medicine segment. CEO Christian Behrenbruch highlighted that the two-product approach is driving gains in both market share and pricing.
PSMA-PET imaging zeroes in on a protein frequently present on prostate cancer cells and is gaining traction for detecting and staging the disease. Telix markets PSMA-PET imaging kits under the names Illuccix and Gozellix.
Telix also revealed that China’s National Medical Products Administration has accepted a New Drug Application for Illuccix, submitted alongside partner Grand Pharmaceutical Group. The company highlighted that its China Phase 3 trial showed a 94.8% positive predictive value, indicating how frequently a positive scan accurately detects cancer. Additionally, over two-thirds of patients experienced changes to their treatment plans following the imaging results.
Investors are also watching Telix’s dealings with U.S. regulators. The company revealed it’s wrapping up a refiling package for Pixclara following a Complete Response Letter — the FDA’s way of saying the current application won’t pass as is. Telix said it’s reached what it sees as agreement with the agency on key points for a Zircaix resubmission after further talks.
Telix’s shares have long been tied to regulatory milestones. Back in August, the stock dropped when the FDA requested additional data on manufacturing and supply chain details for its kidney cancer imaging product.
Risks lurk on both ends of the spectrum. Delays in refilings, concerns over manufacturing comparability, or slower adoption of newer products might weigh on forecasts. At the same time, clinical trial schedules can shift, and reimbursement policies may evolve.
Traders tracking the upcoming session and week will focus on developments in Telix’s U.S. filing efforts and key trial updates the company flagged. This includes an anticipated readout of safety and dosimetry data from Part 1 of its ProstACT Global Phase 3 prostate cancer trial, plus European sites set to join the IPAX-BrIGHT glioblastoma study in Q1 2026.
